USE OF METFORMIN WITH EMPHASIS IN HEART PATIENTS

• Autor(a) principal: Paiva Filho, Pedro Ferreira
• Data de Publicação: 2021
• Outros Autores: Silva, Kelly Gomes da, Passos, Amábylle Costa, Souza, Ana Beatriz Campos de, Mota, Maria Laura Barrocas Rosado, Sousa, Milena Nunes Alves de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista JRG de Estudos Acadêmicos
• Texto Completo: http://revistajrg.com/index.php/jrg/article/view/267

Treatment with metformin is known to significantly improve glucose control in people with type 2 diabetes, with no weight gain and negligible risk of hypoglycemia. In addition, metformin treatment appears to be associated with a lower risk of cardiovascular disease and morbidity. Thus, we aimed to perform a systematic review regarding the use of metformin in the treatment of cardiac patients. This is a systematic review of the literature. To do so, the literature reference selection method was ProKnow-C. The PICO acronym question was: In cardiac patients, can the use of metformin contribute to the treatment of this group? The following uncontrolled terms were used to search the material: "cardiac abnormality", "cardiac treatment", "metformin in cardiac patients". Regarding the inclusion criteria, we included articles published in national and international languages, in the time interval 2010-2021 and that were freely available in the platforms of the National Library of Medicine U.S (NLM/PUBMED), ScienceDirect (Elsevier) and Scientific Electronic Library Online (SciELO). Although metformin is used as a form of treatment in several clinical cases, some authors still claim that there are worrisome results regarding the incidence of cardiovascular deaths. Due to the instability of the articles under analysis, it is suggested by the authors of this study that more clinical trials be carried out in order to consolidate the effects of this drug in patients with cardiovascular problems.